京都大学研究发现CA8可能连接2型糖尿病中肝脏与胰腺功能障碍
Shared signaling regulator may link liver and pancreas dysfunction in type 2 diabetes
发表在Science Advances的研究发现碳酸酐酶VIII(CA8)在胰腺胰岛中高表达、在肝细胞中低表达,与高血糖和胰岛素分泌不足的多器官功能障碍相关。动物实验显示恢复肝脏CA8表达可减少空腹肝糖输出,但该结论目前仅限小鼠模型,尚需人体研究进一步验证。
Maintaining healthy blood glucose levels involves striking a balance between the glucose produced by the liver during fasting and the insulin released from pancreatic beta cells after meals. In type 2 diabetes, glucose production goes into overdrive while insulin secretion becomes insufficient, a multiorgan dysfunction that contributes to hyperglycemia, or high blood glucose levels.
Intracellular calcium signaling is essential to both processes and could represent a crucial link between them, yet a common molecular regulator has yet to be found. While the protein carbonic anhydrase VIII—CA8—is known to bind to IP3R1, a calcium-release channel in the endoplasmic reticulum, and restrain calcium signaling in other tissues, this protein lacks the usual enzyme activity.
However, a team of researchers at Kyoto University found the protein to be enriched in pancreatic islets and hepatocytes and wondered whether CA8 might play a role in controlling metabolic functions in the liver and pancreas. The study is published in the journal Science Advances.
Testing CA8's metabolic role
The team combined metabolic testing of Car8wdl mice—lacking functional CA8—with experiments on the mice's isolated pancreatic islets and liver hepatocytes. They measured insulin secretion, glucose production, calcium responses and gene expression, and then used pharmacological and genetic tests to assess whether the effects depended on IP3R1.
In further experiments, the researchers found that chronic exposure to glucagon, the very hormone that triggers glucose production, increased CA8 expression, which in turn reduced the response to further glucagon stimulation. This glucagon-desensitizing effect mediated by CA8 may provide a mechanistic explanation for the emerging glucagon-based T2D therapy.
The team also analyzed obese and diabetic mice along with public RNA-sequencing data from mice fed high-fat diets and found increased CA8 expression in islets, hinting at the protein's role in T2D pathogenesis.
Opposing changes in liver and pancreas
The team's results reveal CA8 to be a promising therapeutic target. While the CA8-deficient mice showed increased glucose production in the liver and glucose-induced insulin secretion in the pancreas, CA8 expression in obese and diabetic mice shifted in opposite directions, rising in the pancreas' islets while falling in the liver's hepatocytes, consistent with impaired insulin secretion and excessive glucose production.
The team also observed that restoring CA8 expression in the liver reduced excessive hepatic glucose production and hyperglycemia during fasting.
"We were intrigued that a single intracellular regulator could act as a common 'brake' in two organs but produce very different physiological outcomes," says first author Muhammad Fauzi. "That organ-specific duality gives us a new way to think about the multiorgan nature of type 2 diabetes."
Toward coordinated liver and pancreas treatments
This study suggests that a multiorgan disease can arise from tissue-specific changes in a shared molecular mechanism, pointing toward treatment strategies for type 2 diabetes that consider the pancreas and liver as one coordinated glucose-control system rather than targeting either organ in isolation.
However, as much of the physiology was established in mice, further studies in human tissues and cells are necessary before CA8 can be considered a therapeutic target.
"Our findings may help explain part of the complexity of this disease," says corresponding author Takaaki Murakami. "We hope to use this multiorgan perspective to develop treatments that act appropriately in each tissue."
Publication details
Muhammad Fauzi et al, Carbonic anhydrase VIII regulates IP3R1-dependent Ca2+ signaling to coordinate insulin secretion and hepatic glucose production, Science Advances (2026). DOI: 10.1126/sciadv.aeh4948. www.science.org/doi/10.1126/sciadv.aeh4948
Journal information: Science Advances
Key medical concepts
Clinical categories
Who's behind this story?
Sadie Harley
BSc Life Sciences & Ecology. Microbiology lab background with pharmaceutical news experience in oil, gas, and renewable industries. Full profile →
Robert Egan
Bachelor's in mathematical biology, Master's in creative writing. Well-traveled with unique perspectives on science and language. Full profile →
Citation: Shared signaling regulator may link liver and pancreas dysfunction in type 2 diabetes (2026, October 12) retrieved 12 October 2026 from https://medicalxpress.com/news/2026-10-link-liver-pancreas-dysfunction-diabetes.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
来源:Medical Xpress · medicalxpress.com